Engineering a Vascularised 3D in Vitro Model of Cancer Progression
Authors
Affiliations
The hallmark of tumours is the ability of cancerous cells to promote vascular growth, to disseminate and invade to distant organs. The metastatic process is heavily influenced by the extracellular matrix (ECM) density and composition of the surrounding tumour microenvironment. These microenvironmental cues, which include hypoxia, also regulate the angiogenic processes within a tumour, facilitating the spread of cancer cells. We engineered compartmentalized biomimetic colorectal tumouroids with stromal surrounds that comprised a range of ECM densities, composition and stromal cell populations. Recapitulating tissue ECM composition and stromal cell composition enhanced cancer cell invasion. Manipulation of ECM density was associated with an altered migration pattern from glandular buds (cellular aggregates) to epithelial cell sheets. Laminin appeared to be a critical component in regulating endothelial cell morphology and vascular network formation. Interestingly, the disruption of vascular networks by cancer cells was driven by changes in expression of several anti-angiogenic genes. Cancer cells cultured in our biomimetic tumouroids exhibited intratumoural heterogeneity that was associated with increased tumour invasion into the stroma. These findings demonstrate that our 3D in vitro tumour model exhibits biomimetic attributes that may permit their use in studying microenvironment clues of tumour progression and angiogenesis.
Dense Collagen I as a Biomimetic Material to Track Matrix Remodelling in Renal Carcinomas.
Upadhyay A, Bakkalci D, Micalet A, Butler M, Bergin M, Moeendarbary E ACS Omega. 2024; 9(40):41419-41432.
PMID: 39398183 PMC: 11465592. DOI: 10.1021/acsomega.4c04442.
Advancements in 3D In Vitro Models for Colorectal Cancer.
Vitale S, Calapa F, Colonna F, Luongo F, Biffoni M, De Maria R Adv Sci (Weinh). 2024; 11(32):e2405084.
PMID: 38962943 PMC: 11348154. DOI: 10.1002/advs.202405084.
A comprehensive review of 3D cancer models for drug screening and translational research.
Sharma K, Dey S, Karmakar R, Rengan A Cancer Innov. 2024; 3(1):e102.
PMID: 38948533 PMC: 11212324. DOI: 10.1002/cai2.102.
Mathur S, Srivastava P, Srivastava A, Rai N, Abbas S, Kumar A BMC Cancer. 2024; 24(1):323.
PMID: 38459456 PMC: 10921801. DOI: 10.1186/s12885-024-12064-5.
Bakkalci D, Al-Badri G, Yang W, Nam A, Liang Y, Khurram S Mater Today Bio. 2024; 24:100923.
PMID: 38226014 PMC: 10788620. DOI: 10.1016/j.mtbio.2023.100923.